Investigating an antibody that targets cancer cells by inhibiting DNA repair
Official title: Structure-Function Studies of a Cell Penetrating Antibody that Inhibits DNA Repair
Funded at Yale University · NIH-10792940 · Data updated 2026-11-12
This study is exploring a special antibody called 3E10 that helps make certain cancer cells more vulnerable to radiation therapy, aiming to create a new treatment that could help patients with specific types of cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $223,174 |
| NIH project number | 5R21CA278934-02 |
| Project ID | NIH-10792940 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are BRCA2- or PTEN-deficient, as well as those who may benefit from enhanced radiation therapy.
✕Less likely to help
Patients with cancers that do not exhibit BRCA2 or PTEN deficiencies may not receive benefit from this research.
What this research studies
This research focuses on a unique antibody called 3E10, which has the ability to penetrate cancer cells and inhibit a key protein involved in DNA repair. By blocking this protein, the antibody makes cancer cells more sensitive to radiation therapy and can be particularly effective against tumors that lack certain DNA repair mechanisms. The research involves a combination of laboratory studies, including structural analysis and tests in animal models, to understand how this antibody works and to enhance its effectiveness against tumors. The goal is to develop a new treatment approach that could improve outcomes for patients with specific types of cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and kill cancer cells while sparing healthy tissues.
How similar studies have gone: Other research has shown promising results with similar approaches using cell-penetrating antibodies to target cancer cells, indicating potential for success in this area.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Glazer, Peter M — Yale University
- Study coordinator: Glazer, Peter M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.